KR20220110859A - 악성 종양 치료용 제제 및 조성물 - Google Patents

악성 종양 치료용 제제 및 조성물 Download PDF

Info

Publication number
KR20220110859A
KR20220110859A KR1020227025906A KR20227025906A KR20220110859A KR 20220110859 A KR20220110859 A KR 20220110859A KR 1020227025906 A KR1020227025906 A KR 1020227025906A KR 20227025906 A KR20227025906 A KR 20227025906A KR 20220110859 A KR20220110859 A KR 20220110859A
Authority
KR
South Korea
Prior art keywords
group
acceptable salt
pharmaceutically acceptable
compound
antitumor
Prior art date
Application number
KR1020227025906A
Other languages
English (en)
Korean (ko)
Inventor
아키히로 미우라
히로시 소오토메
Original Assignee
다이호야쿠힌고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이호야쿠힌고교 가부시키가이샤 filed Critical 다이호야쿠힌고교 가부시키가이샤
Priority to KR1020247001654A priority Critical patent/KR20240014585A/ko
Publication of KR20220110859A publication Critical patent/KR20220110859A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227025906A 2016-03-04 2017-03-03 악성 종양 치료용 제제 및 조성물 KR20220110859A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247001654A KR20240014585A (ko) 2016-03-04 2017-03-03 악성 종양 치료용 제제 및 조성물

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JPJP-P-2016-042662 2016-03-04
JP2016042662 2016-03-04
PCT/JP2017/008599 WO2017150725A1 (fr) 2016-03-04 2017-03-03 Préparation et composition de traitement de tumeurs malignes
KR1020187028052A KR20180118719A (ko) 2016-03-04 2017-03-03 악성 종양 치료용 제제 및 조성물

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187028052A Division KR20180118719A (ko) 2016-03-04 2017-03-03 악성 종양 치료용 제제 및 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247001654A Division KR20240014585A (ko) 2016-03-04 2017-03-03 악성 종양 치료용 제제 및 조성물

Publications (1)

Publication Number Publication Date
KR20220110859A true KR20220110859A (ko) 2022-08-09

Family

ID=59743095

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020227025906A KR20220110859A (ko) 2016-03-04 2017-03-03 악성 종양 치료용 제제 및 조성물
KR1020247001654A KR20240014585A (ko) 2016-03-04 2017-03-03 악성 종양 치료용 제제 및 조성물
KR1020187028052A KR20180118719A (ko) 2016-03-04 2017-03-03 악성 종양 치료용 제제 및 조성물

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020247001654A KR20240014585A (ko) 2016-03-04 2017-03-03 악성 종양 치료용 제제 및 조성물
KR1020187028052A KR20180118719A (ko) 2016-03-04 2017-03-03 악성 종양 치료용 제제 및 조성물

Country Status (8)

Country Link
US (1) US11975002B2 (fr)
EP (1) EP3424505A4 (fr)
JP (2) JP7085985B2 (fr)
KR (3) KR20220110859A (fr)
AU (1) AU2017226389B2 (fr)
MA (1) MA43807A (fr)
TW (1) TWI782906B (fr)
WO (1) WO2017150725A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3023101B1 (fr) 2013-07-18 2020-08-19 Taiho Pharmaceutical Co., Ltd. Agent thérapeutique pour un cancer résistant à un inhibiteur de fgfr
TR201907147T4 (tr) 2013-07-18 2019-06-21 Taiho Pharmaceutical Co Ltd Fgfr inhibitörünün aralıklı uygulanmasına yönelik anti-tümör ilaç.
AU2016240841C1 (en) 2015-03-31 2018-05-17 Taiho Pharmaceutical Co., Ltd. Crystal of 3,5-disubstituted benzene alkynyl compound
AU2017226389B2 (en) * 2016-03-04 2023-02-02 Taiho Pharmaceutical Co., Ltd. Preparation and composition for treatment of malignant tumors
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
FI3466934T3 (fi) 2016-05-31 2024-04-23 Taiho Pharmaceutical Co Ltd Sulfonamidiyhdisteitä tai niiden suola ribonukleotidireduktaasin inhibiittoreina syövän hoitamiseksi
MA51228A (fr) * 2017-11-29 2020-10-07 Taiho Pharmaceutical Co Ltd Agent antitumoral
PL3769765T3 (pl) * 2018-03-19 2024-06-10 Taiho Pharmaceutical Co., Ltd. Kompozycja farmaceutyczna zawierająca alkilosiarczan sodu
WO2020095452A1 (fr) 2018-11-09 2020-05-14 大鵬薬品工業株式会社 Procédé de fabrication de composé diméthoxybenzène
WO2020096042A1 (fr) 2018-11-09 2020-05-14 大鵬薬品工業株式会社 Procédé de fabrication de composé diméthoxybenzène
TWI791928B (zh) 2018-11-26 2023-02-11 日商大鵬藥品工業股份有限公司 透過併用纖維母細胞生長因子受體抑制劑與內分泌療法來治療及預防可適用內分泌療法之腫瘤的方法
WO2020170355A1 (fr) * 2019-02-20 2020-08-27 大鵬薬品工業株式会社 Procede pour le traitement de tumeurs a variant du fgfr1
EP3932427A4 (fr) * 2019-02-28 2022-12-07 Taiho Pharmaceutical Co., Ltd. Thérapie anticancéreuse faisant appel à un composé benzène-alcynyle 3,5-disubstitué et au pembrolizumab
WO2020256096A1 (fr) * 2019-06-21 2020-12-24 大鵬薬品工業株式会社 Méthode de traitement d'une tumeur maligne
US20230165862A1 (en) * 2020-04-10 2023-06-01 Taiho Pharmaceutical Co., Ltd. Cancer therapy using 3,5-disubstituted benzene alkynyl compound and mek inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013108809A1 (fr) 2012-01-19 2013-07-25 大鵬薬品工業株式会社 Composé d'alkynylbenzène 3,5-disubstitué et un sel de celui-ci
WO2015008844A1 (fr) 2013-07-18 2015-01-22 大鵬薬品工業株式会社 Agent thérapeutique pour un cancer résistant à un inhibiteur de fgfr
WO2015008839A1 (fr) 2013-07-18 2015-01-22 大鵬薬品工業株式会社 Médicament antitumoral pour l'administration intermittente d'inhibiteur de fgfr

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3433239A1 (de) 1984-09-11 1986-03-20 Bayer Ag, 5090 Leverkusen Feste arzneizubereitung enthaltend nitrendipin und verfahren zu ihrer herstellung
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
JP4117811B2 (ja) 1997-04-22 2008-07-16 日本化薬株式会社 フルタミド製剤及びその製法
HU230251B1 (hu) 2000-07-19 2015-11-30 Warner-Lambert Co. 4-Jód-fenil-amino-benzhidroxámsav-észter-származékok és ezeket tartalmazó gyógyászati készítmények
PL401637A1 (pl) 2002-03-13 2013-05-27 Array Biopharma Inc. N3 alkilowane pochodne benzimidazolu jako inhibitory MEK
JP4409430B2 (ja) 2002-07-03 2010-02-03 小野薬品工業株式会社 免疫賦活組成物
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
US20040102360A1 (en) 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
WO2005051302A2 (fr) 2003-11-19 2005-06-09 Array Biopharma Inc. Inhibiteurs bicycliques de mek, et leurs procedes d'utilisation
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
ES2397825T3 (es) 2004-06-11 2013-03-11 Japan Tobacco, Inc. Derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetrahidro-2H-pirido[2,3-d]pirimidina y compuestos relacionados para el tratamiento del cáncer
SI1802579T1 (sl) 2004-10-20 2014-03-31 Merck Serono Sa Derivati 3-arilaminopiridina
CA2611030A1 (fr) 2005-06-17 2006-12-21 Pfizer Inc. Composes d'acide alpha-(aryl-ou heteroaryl-methyl)-beta-piperidinopropanoique utiles en tant qu'antagonistes du recepteur orl1
CA2618218C (fr) 2005-07-21 2015-06-30 Ardea Biosciences, Inc. Inhibiteurs n-(arylamino)-sulfonamide de mek
CA2624882C (fr) 2005-10-06 2014-05-20 Schering Corporation Pyrazolopyrimidines en tant qu'inhibiteurs de proteines kinases
BRPI0617165B1 (pt) 2005-10-07 2023-10-03 Exelixis Inc Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
US8648087B2 (en) 2005-11-15 2014-02-11 Array Biopharma, Inc. N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
JP5156644B2 (ja) 2006-01-25 2013-03-06 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー 不飽和ｍＴＯＲ阻害剤
ATE496623T1 (de) 2006-04-26 2011-02-15 Supernus Pharmaceuticals Inc Oxcarbazepin-zubereitungen für kontrollierte freisetzung mit sigmoidalem freisetzungsprofil
SE530029C2 (sv) 2006-06-28 2008-02-12 Volvo Lastvagnar Ab Position för drivlina
EP1939197A1 (fr) 2006-12-22 2008-07-02 Schwarz Pharma Ag Derivés de 8-éthinylxanthine comme antagonistes selectives du recepteur A2A
WO2008093855A1 (fr) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. Composition destinée au traitement d'un cancer de l'estomac de type indifférencié
CA2681756C (fr) 2007-03-28 2015-02-24 Pharmacyclics, Inc. Inhibiteurs de la tyrosine kinase de bruton
BRPI0810206A2 (pt) 2007-04-10 2014-10-21 Exelixis Inc Método de tratar câncer
PT2203181T (pt) 2007-10-16 2018-05-10 Biocon Ltd Uma composição farmacêutica sólida para administração por via oral e o seu processo de fabrico
AU2009261683A1 (en) * 2008-06-19 2009-12-23 Astrazeneca Ab Pyrazole compounds 436
US20110053866A1 (en) 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB0819105D0 (en) 2008-10-17 2008-11-26 Chroma Therapeutics Ltd Pyrrolo-pyrimidine compounds
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
WO2010107991A2 (fr) 2009-03-18 2010-09-23 Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Utilisation d'ixolaris, un inhibiteur de facteur tissulaire, pour le traitement et la prévention du cancer
CA2759083A1 (fr) 2009-04-30 2010-11-04 Novartis Ag Derives d'imidazole et leur utilisation comme modulateurs des kinases dependantes des cyclines
KR101483215B1 (ko) 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
EP2547698B1 (fr) 2010-03-14 2015-07-29 The Translational Genomics Research Institute Procédés de détermination de la sensibilité de tumeurs à des inhibiteurs de la tyrosine kinase
DE102011015188A1 (de) 2010-03-29 2011-09-29 Herbert Kannegiesser Gmbh Verfahren zur Nassbehandlung, insbesondere zum Reinigen, von Gegenständen
CA3240281A1 (fr) 2010-06-03 2011-12-08 Pharmacyclics Llc Utilisation d'inhibiteurs de la tyrosine-kinase de bruton dans le traitement du lymphome folliculaire
AR083417A1 (es) 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
MX342064B (es) * 2011-04-06 2016-09-12 Taiho Pharmaceutical Co Ltd Novedoso compuesto de imidazo-oxazina o sal del mismo.
WO2013088191A1 (fr) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagoniste du récepteur 3 du facteur de croissance des fibroblastes (fgfr3) à utiliser dans le traitement ou la prévention de troubles squelettiques liés à une activation anormale du fgfr3
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
CA2861377A1 (fr) 2012-01-31 2013-08-08 Novartis Ag Combinaison d'un inhibiteur de rtk avec un anti-oestrogene et son utilisation pour traiter le cancer
CA2865021C (fr) 2012-02-23 2020-06-30 Bayer Intellectual Property Gmbh Pyrrolotriazines de benzothienyle substitues et leurs utilisations
RU2618423C2 (ru) 2012-07-02 2017-05-03 Тайхо Фармасьютикал Ко., Лтд. Усилитель противоопухолевого эффекта, содержащий имидазооксазиновое соединение
CN103570725B (zh) 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
CA2889993A1 (fr) 2012-11-26 2014-05-30 Roche Innovation Center Copenhagen A/S Compositions et methodes pour la modulation de l'expression de fgfr3
JP2016510751A (ja) * 2013-03-06 2016-04-11 ジェネンテック， インコーポレイテッド 抗がん剤耐性を治療及び予防する方法
CN109776525B (zh) * 2013-04-19 2022-01-21 因赛特控股公司 作为fgfr抑制剂的双环杂环
EP3543355B1 (fr) 2013-06-20 2020-12-23 Taiho Pharmaceutical Co., Ltd. Méthode de prédiction de l'efficacité thérapeutique d'un inhibiteur de pi3k/akt/mtor d'après l'expression de phlda1 ou pik3c2b
RU2595862C2 (ru) 2013-09-03 2016-08-27 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Способ профилактики или лечения заболеваний, связанных с пониженной плотностью интерфероновых рецепторов
SG10201808565QA (en) 2014-03-31 2018-11-29 Debiopharm Int Sa Fgfr fusions
WO2015163448A1 (fr) 2014-04-25 2015-10-29 中外製薬株式会社 Préparation contenant un composé tétracyclique à haute dose
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
HUE058219T2 (hu) * 2014-09-26 2022-07-28 Janssen Pharmaceutica Nv FGFR-mutánsgénpanel alkalmazása olyan rákbetegek azonosításában, akik FGFR-inhibitorral történõ kezelésre reszponzívak lesznek
JP2017535528A (ja) 2014-10-03 2017-11-30 ノバルティス アーゲー 組み合わせ治療
MA41350A (fr) 2015-01-14 2017-11-21 Janssen Pharmaceutica Nv Synthèse d'un inhibiteur de la tyrosine kinase de bruton
CN105859721B (zh) 2015-01-22 2018-04-17 浙江京新药业股份有限公司 一种伊布鲁替尼的制备方法
EP3253733B1 (fr) 2015-02-05 2020-04-29 TyrNovo Ltd. Combinaisons de doubles modulateurs d'irs/stat3 et d'agents anticancéreux pour le traitement du cancer
WO2016130917A1 (fr) 2015-02-12 2016-08-18 Memorial Sloan Kettering Cancer Center Traitement contre le cancer à action synergique
CN107428779A (zh) 2015-02-27 2017-12-01 大鹏药品工业株式会社 咪唑并噁嗪晶体、含有所述晶体的药物组合物和制备所述晶体的方法
AU2016240841C1 (en) 2015-03-31 2018-05-17 Taiho Pharmaceutical Co., Ltd. Crystal of 3,5-disubstituted benzene alkynyl compound
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
US10532056B2 (en) 2015-06-29 2020-01-14 Verastem, Inc. Therapeutic compositions, combinations, and methods of use
CA2991846A1 (fr) 2015-07-24 2017-02-02 Anne VASLIN-CHESSEX Expression de fgfr et sensibilite a un inhibiteur du fgfr
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
EP3365335B1 (fr) * 2015-10-23 2024-02-14 Array Biopharma, Inc. Composés de 2-pyridazin-3(2h)-one à substitution 2-aryle et 2-hétéroaryle utilisés en tant qu'inhibiteurs de fgfr tyrosine kinases
JP6860919B2 (ja) 2015-11-19 2021-04-21 国立大学法人金沢大学 間葉系ｋｒａｓ変異型がん治療剤
AU2017226389B2 (en) * 2016-03-04 2023-02-02 Taiho Pharmaceutical Co., Ltd. Preparation and composition for treatment of malignant tumors
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
US20190224341A1 (en) * 2016-06-29 2019-07-25 The General Hospital Corporation Renal clearable organic nanocarriers
JP2018002662A (ja) 2016-07-01 2018-01-11 大鵬薬品工業株式会社 キノリルピロロピリミジル縮合環化合物を合成するために有用な中間体
WO2018130928A1 (fr) 2017-01-10 2018-07-19 Novartis Ag Combinaison pharmaceutique comprenant un inhibiteur d'alk et un inhibiteur de shp2
EP3679159A1 (fr) 2017-09-08 2020-07-15 H. Hoffnabb-La Roche Ag Méthodes diagnostiques et thérapeutiques du cancer
PL3769765T3 (pl) * 2018-03-19 2024-06-10 Taiho Pharmaceutical Co., Ltd. Kompozycja farmaceutyczna zawierająca alkilosiarczan sodu
WO2020095452A1 (fr) 2018-11-09 2020-05-14 大鵬薬品工業株式会社 Procédé de fabrication de composé diméthoxybenzène
WO2020096042A1 (fr) 2018-11-09 2020-05-14 大鵬薬品工業株式会社 Procédé de fabrication de composé diméthoxybenzène
CN111223693A (zh) 2018-11-26 2020-06-02 福特全球技术公司 开关总成
TWI791928B (zh) 2018-11-26 2023-02-11 日商大鵬藥品工業股份有限公司 透過併用纖維母細胞生長因子受體抑制劑與內分泌療法來治療及預防可適用內分泌療法之腫瘤的方法
WO2020170355A1 (fr) 2019-02-20 2020-08-27 大鵬薬品工業株式会社 Procede pour le traitement de tumeurs a variant du fgfr1
EP3932427A4 (fr) 2019-02-28 2022-12-07 Taiho Pharmaceutical Co., Ltd. Thérapie anticancéreuse faisant appel à un composé benzène-alcynyle 3,5-disubstitué et au pembrolizumab
WO2020256096A1 (fr) 2019-06-21 2020-12-24 大鵬薬品工業株式会社 Méthode de traitement d'une tumeur maligne

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013108809A1 (fr) 2012-01-19 2013-07-25 大鵬薬品工業株式会社 Composé d'alkynylbenzène 3,5-disubstitué et un sel de celui-ci
WO2015008844A1 (fr) 2013-07-18 2015-01-22 大鵬薬品工業株式会社 Agent thérapeutique pour un cancer résistant à un inhibiteur de fgfr
WO2015008839A1 (fr) 2013-07-18 2015-01-22 大鵬薬品工業株式会社 Médicament antitumoral pour l'administration intermittente d'inhibiteur de fgfr

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Cancer Res., 2085-2094(2010)
Clin Cancer Res. 2572-83(2013)
Drug Resistance Updates 9(2006), 1-18
J. Clin. Oncol. 24, 3664-3671(2006)
Mol. Cancer Res. 3, 655-667(2005)
Nature. 26; 487(7408): 505-9(2012)
Oncotarget. 2009-22(2015)

Also Published As

Publication number Publication date
AU2017226389B2 (en) 2023-02-02
RU2018134777A (ru) 2020-04-06
TW201733590A (zh) 2017-10-01
JP7085985B2 (ja) 2022-06-17
KR20180118719A (ko) 2018-10-31
TWI782906B (zh) 2022-11-11
EP3424505A1 (fr) 2019-01-09
RU2018134777A3 (fr) 2020-06-01
WO2017150725A1 (fr) 2017-09-08
KR20240014585A (ko) 2024-02-01
US11975002B2 (en) 2024-05-07
AU2017226389A1 (en) 2018-10-25
JPWO2017150725A1 (ja) 2019-01-17
US20200281927A1 (en) 2020-09-10
MA43807A (fr) 2018-11-28
EP3424505A4 (fr) 2019-10-16
JP2022024025A (ja) 2022-02-08
AU2017226389A2 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
JP7085985B2 (ja) 悪性腫瘍治療用製剤及び組成物
US11883404B2 (en) Preparation and composition for treatment of malignant tumors
KR20070050478A (ko) 세포 증식과 관련된 질환 치료용 배합물
JP2021176819A (ja) キナゾリン化合物を有効成分とする医薬組成物
TWI803480B (zh) 用於增加血漿2'-去氧尿苷(dUrd)及胸苷酸合成酶抑制之方法
EP3053578B1 (fr) Polythérapie contre le cancer utilisant un composé azabicyclo
JP2023512040A (ja) 化合物及びその使用
JP7183371B2 (ja) 抗腫瘍剤、抗腫瘍効果増強剤及び抗腫瘍用キット
KR20170134462A (ko) Mdm2 저해제와 btk 저해제의 병용 치료법
CN113194952A (zh) Hdm2-p53相互作用抑制剂和bcl2抑制剂的组合及其治疗癌症的用途
KR20160050026A (ko) 항 종양제 및 항 종양 효과 증강제
KR20190110581A (ko) 암 치료
EP2513089B1 (fr) Composés de 3-(indolyl)- ou 3-(azaindolyl)-4-arylmaléimide et leur utilisation dans le traitement de tumeurs
TW201321383A (zh) 用於預防及治療非小細胞肺癌之包含吡嗪并三嗪衍生物的組成物
WO2014002922A1 (fr) Méthode de traitement du cancer par l'utilisation combinée d'un agent anti-cancéreux
WO2015125641A1 (fr) Composition pharmaceutique contenant un dérivé de camptothécine polymérisé, et dérivé inhibiteur de hsp90 polymérisé
RU2777595C2 (ru) Препарат и композиция для лечения злокачественных опухолей
JP7311177B2 (ja) Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用
JP2014034531A (ja) Ｈｓｐ９０阻害剤とゲムシタビンの組み合わせ
WO2024214771A1 (fr) Conjugué de dextrane et d'agoniste de tlr7
TW201008945A (en) Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents
JP2015163592A (ja) 抗癌剤の併用による癌治療方法
JP2016088863A (ja) Ｒｅｔ阻害薬耐性癌に対する治療剤
CN118680935A (zh) Sos1抑制剂化合物与其他抗肿瘤药物的联用用途
EA045240B1 (ru) Способы лечения рака

Legal Events

Date Code Title Description
A107 Divisional application of patent
E902 Notification of reason for refusal
E601 Decision to refuse application
A107 Divisional application of patent